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Review Article
A systematic review of the evidence on the
treatment of rapid cycling bipolar disorder
Rapid cycling is a descriptive term that refers to
the presence of four or more discrete mood
episodes during a one-year period in the context
of bipolar disorder. In the DSM-IV, rapid cycling
is a course speciﬁer for bipolar disorder and is
deﬁned by the occurrence of at least four mood
episodes (mania, hypomania, depression, or
mixed) during the preceding year (1). The term
rapid cycling was ﬁrst coined in 1974, when
Dunner and Fieve (2) described a group of
lithium-unresponsive manic-depressive patients
who were noted to have at least four episodes of
mania and ⁄or depression per year. Clinical studies
which thereafter investigated the correlates of
rapid cycling bipolar disorder have suggested that
it is more frequent in women and is associated
with hypothyroidism and bipolar II disorder (3).
The clinical importance of this condition derives
from its relatively high point prevalence (ranging
from 10% to 20% among clinical samples) (1) and
its associations with longer illness duration (4)
and greater illness severity. Indeed, patients who
experience a rapid cycling course have been
reported to demonstrate a worse global functioning
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Objective: Rapid cycling is associated with longer illness duration and
greater illness severity in bipolar disorder. The aim of the present study
was to review the existing published randomized trials investigating the
eﬀect of treatment on patients with rapid cycling bipolar disorder.
Methods: A MEDLINE search was conducted using combinations of
the following key words: bipolar and rapid or rapid-cycling or rapid
cycling and randomized. The search was conducted through July 16,
2011, and no conference proceedings were included.
Results: The search returned 206 papers and ultimately 25 papers were
selected for review. Only six randomized, controlled trials speciﬁcally
designed to study a rapid cycling population were found. Most data were
derived from post hoc analyses of trials that had included rapid cyclers.
The literature suggested that: (i) rapid cycling patients perform worse in
the follow-up period; (ii) lithium and anticonvulsants have comparable
eﬃcacies; (iii) there is inconclusive evidence on the comparative acute or
prophylactic eﬃcacy of the combination of anticonvulsants versus
anticonvulsant monotherapy; (iv) aripiprazole, olanzapine, and
quetiapine are eﬀective against acute bipolar episodes; (v) olanzapine
and quetiapine appear to be equally eﬀective to anticonvulsants during
acute treatment; (vi) aripiprazole and olanzapine appear promising for
the maintenance of response of rapid cyclers; and (vii) there might be an
association between antidepressant use and the presence of rapid cycling.
Conclusion: The literature examining the pharmacological treatment
of rapid cycling is still sparse and therefore there is no clear consensus
with respect to its optimal pharmacological management. Clinical trials
speciﬁcally studying rapid cycling are needed in order to unravel the
appropriate management of rapid cycling bipolar disorder.
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(5) and may be at a higher risk for serious suicide
attempts (6). However, controversies still exist
regarding the necessary criteria for diagnosis, the
etiology, the longitudinal stability (7), and treat-
ment of rapid cycling.
Several strategies have been used to treat this
condition, given that a rapid cycling course has
been recognized as an independent predictor of
inadequate treatment response in bipolar disorder
(2, 8). Studies have investigated the eﬀects of the
standard mood stabilizers (lithium, divalproex, and
carbamazepine) used either as monotherapy or in
combination, and also the utility of atypical
antipsychotics and antidepressants (9). The role
of antidepressants in the development of rapid
cycling still remains an issue of debate, with some
studies associating them with the onset or worsen-
ing of rapid cycling (10, 11), while others fail to
replicate this association after controlling for
major depression (6, 12). In the search for more
eﬀective treatment approaches, even experimental
agents such as levothyroxine or melatonin have
been employed, with mixed results (9, 13–16). The
number of studies that have investigated the
pharmacological management of rapid cycling is
limited, and there are only a few that have directly
compared speciﬁc treatment alternatives for rapid
cycling patients. Additionally, the number of trials
using a randomized design was also few. Conse-
quently, there is no clear consensus with respect to
the optimal pharmacological management of rapid
cycling.
The aim of the current paper was to review
published randomized clinical trials assessing the
eﬃcacy of various treatments in acute mood
episodes and in prevention of relapse of mood
episodes in patients with rapid cycling bipolar
disorder.
Materials and methods
A MEDLINE search was conducted using combi-
nations of the following key words: bipolar and
rapid or rapid-cycling or rapid cycling and random-
ized. The search was conducted through July 16,
2011, and no conference proceedings were included.
Results
The search returned 206 papers for initial evalua-
tion. Papers from randomized studies and their
post hoc analyses reporting separate data on acute
or maintenance treatment response for patients
with a rapid cycling course or in which the majority
of patients were rapid cyclers were selected.
Twenty-ﬁve papers that presented such results
were found, 24 of which reported on the original
or post hoc analysis data, and one of which was a
meta-analysis that included randomized as well as
non-randomized studies. It is important to mention
that most studies presented the eﬀects of treat-
ments in rapid cycling patients; however, there
were also studies comparing the eﬃcacy of treat-
ment in rapid versus non-rapid cycling bipolar
disorder patients (17–27). Table 1 lists the details
of these studies; however, some of the studies
shown in the table provide diﬀerent analyses of
pivotal trials and should not be considered sepa-
rate trials (olanzapine studies).
Treatment of acute mood episodes in patients with rapid
cycling bipolar course
Antidepressant monotherapy
Escitalopram. In the Parker et al. study (28), 10
outpatients having a diagnosis of bipolar II disor-
der and a history of mood episodes that occurred
at least monthly were recruited. Patients were
required to not have previously received any
antidepressant, mood-stabilizing, or neuroleptic
medication. The study was a randomized, double-
blind, placebo-controlled, cross-over trial of escit-
alopram (10 mg) versus placebo with a nine-month
duration. There was a no-treatment baseline period
of three months (baseline phase) to ensure that
subjects met criteria for episode frequency. Sub-
jects compliant with and completing baseline
period requirements were then randomized to
receive escitalopram or placebo for three months
(phase 2), and then crossed over to receive the
alternative compound for the ﬁnal three-month
period (phase 3). Subjects were assessed at the start
of the study, and every month thereafter for the
entire nine-month period. Parker et al. reported
that escitalopram reduced the severity of depressive
episodes as measured by the Hamilton Depression
Rating Scale (HDRS) and also reduced the per-
centage of days high or low and impaired when
compared with placebo. A weak trend for reduc-
tion in hypomania failed to support concerns that
prescriptions of antidepressants would increase
switch rates in patients with bipolar disorder. The
study did not provide data on the eﬀects of
escitalopram on depression remission rates. In
terms of its funding, the study was not sponsored
by a pharmaceutical company, but rather, the
manufacturer of escitalopram provided the study
capsules, as acknowledged by the authors. How-
ever, it should be noted that the small sample size
should be taken into account when interpreting
these ﬁndings, and the fact that the study was not
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Table 1. Treatment of rapid cycling bipolar disorder
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Acute treatment
Antidepressant monotherapy
Escitalopram
Parker et al.
2006 (28)
Escitalopram
versus PLA
9-month RCT with
cross-over (3 months
drug-free, 3 months
escitalopram,
3 months PLA)
N = 10 medication
-naı¨ve BD-II rapid
cycling patients
(at least monthly
episodes):
Depressed (n = 6)
Euthymic (n = 4)
Primary outcome:
not defined
Escitalopram: (i)
significant
reduction in
depression
(HDRS) severity,
percentage of
days depressed
or high, and
percentage of
days impaired
versus PLA; (ii)
no worsening of
illness course; (iii)
remission of
depression: not
reported
No Escitalopram > PLA Switching to
(hypo)mania:
weak
reduction
with
escitalopram
Venlafaxine
Amsterdam
et al. 2009 (17)
VENLF versus LITH
Post hoc analysis of one
12-week randomized,
parallel-group, open-label
study
Rapid cyclers versus
non-rapid cyclers
(lifetime history)
presenting with a
BD-II MDE
VENLF (n = 12)
LITH (n = 15)
Primary outcome:
HDRS-28 rating
VENLF: (i) greater
reduction in HDRS-28
versus LITH, higher
rate of responders
and remitters; (ii)
equal pro
portion of mood
conversions versus
LITH in rapid
cyclers; (iii) no
significant
differences in
mean YMRS
change scores
over time,
between rapid
and non-rapid
cycling patients;
(iv) remission of
depression:
higher rates
of remitters
in VENLF-
treated
patients
No VENLF > LITH No difference
in mood
switch
between
VENLF and
LITH
Antipsychotic monotherapy
Aripiprazole
Suppes et al.
2008 (29)
ARI versus PLA
Post hoc analysis of two
pooled 3-week RCTs
in rapid cyclers (past
12 months) with an
acute manic or mixed
BD-I episode
N = 103:
ARI (n = 52)
PLA (n = 51)
Primary outcome:
YMRS change
ARI: significantly reduced
mean YMRS total scores
at endpoint in rapid
cycling patients and
greater responder and
remitter rates versus PLA
Yes ARI > PLA Not reported
Bipolar disorder rapid cycling treatment review
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Olanzapine
Suppes et al.
2005 (21)
OLAN versus DIVAL
Post hoc analysis
for rapid cyclers
(past 12 months)
of one 47-week
RCT comparing
OLAN to DIVAL
for bipolar manic
or mixed episodes
Rapid cyclers (n = 144):
OLAN (n = 76)
DIVAL (n = 68)
Non-rapid
cyclers (n = 106)
Primary outcome:
YMRS change
(i) Rapid cycling patients
did less well during the
extended observation
period than non-rapid
cycling patients,
regardless of treatment;
(ii) rapid cycling patients
receiving DIVAL
appeared to be at
some advantage over
non-rapid cycling
patients receiving DIVAL
in terms of manic
symptoms improvement;
(iii) among rapid cycling
patients, OLAN and
DIVAL appeared equal
in YMRS change while
among non-rapid cycling
patients OLAN appeared
superior; (iv) there was a
difference in response
over time in HDRS,
independently of
treatment; (v) no
differences in CGI
severity scale between
rapid cycling groups; (vi)
remission: not reported
Yes OLAN = DIVAL Rapid
cyclers
demonstrate a
non-significant trend
to switch into
depression
more often,
regardless
of treatment
Vieta et al.
2004 (19)
OLAN versus PLA
Post hoc analysis
for rapid cycling
(past 12 months)
manic patients from
two randomized
clinical trials
Rapid cyclers (n = 90):
OLAN (n = 44)
PLA (n = 46)
Non-rapid cyclers
(n = 164)
Primary outcome
not defined
Clinical response rates:
OLAN = 76.7%
PLA = 50%
(i) Improvement of mania
was similar in rapid
cyclers and non-rapid
cyclers; (ii) rapid cyclers
showed an earlier
response; (iii) remission:
in fewer patients with a
rapid cycling course
Yes OLAN > PLA Rapid
cyclers
more likely
to switch into
depression
Shi et al.
2004 (20)
OLAN versus PLA
Post hoc analysis of
one 3-week and one
4-week RCT to
determine the effect of
olanzapine on
the PANSS-Cognitive
score
N = 254 (35%
rapid cyclers)
Primary outcome:
PANSS-Cognitive
score
OLAN-treated patients
experienced modest but
significant improvement
in PANSS-Cognitive
score, regardless of
course (rapid or
non-rapid cycling)
Remission: not
applicable
Yes OLAN > PLA Not applicable
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Baldessarini
et al. 2003 (18)
OLAN versus PLA
Post hoc analysis of
pooled data from one
3-week and one
4-week RCT in manic
patients among 10
subgroup pairs of
interest (including
rapid cyclers during
the previous year)
Rapid cyclers (n = 54):
OLAN (n = 33)
PLA (n = 21)
Primary outcome:
antimanic treatment
efficacy (proportion
of subjects
attaining ‡ 50% YMRS
reduction)
(i) Similar drug ⁄PLA
superiority and
responsiveness to OLAN
was found and responses
were independent of
recent rapid cycling; (ii)
patients who were
relatively more responsive
to OLAN were younger at
illness onset, lacked prior
substance abuse, and
had not previously
received AP treatment;
(iii) remission:
not reported
Yes OLAN > PLA Not reported
Sanger et al.
2003 (31)
OLAN versus PLA
A priori planned
secondary sub
-analysis for patients
with a rapid cycling
course (in the
preceding year)
recruited in one 3-
week RCT in acutely ill
manic or mixed BD
patients
Rapid cyclers (n = 45):
OLAN (n = 19)
PLA (n = 26)
Primary outcome:
change in YMRS
Clinical response
rates:
OLAN = 58%
PLA = 28%
(i) Significantly fewer
PLA patients completed
treatment, and more than
half discontinued due
to lack of efficacy;
(ii) OLAN reduced
YMRS total
scores significantly
more than PLA; (iii)
clinical responses,
defined as ‡ 50%
improvement in
YMRS, were achieved
in 58% of OLAN
patients, compared
with 28% of
PLA patients;
(iv) remission: not
reported
Yes OLAN > PLA Not reported
Quetiapine
Suppes et al.
2010 (22)
QUET versus PLA
Post hoc analysis of
one 8-week RCT in
acutely depressed
adults with BD-I or BD-
II, with or without rapid
cycling in the previous
12 months
Rapid cyclers (n = 74):
QUET (n = 36)
PLA (n = 38)
Primary outcome:
change in MADRS
QUET XR 300 mg
once daily was
significantly more
effective (change in
MADRS) than PLA in
patients with a rapid
cycling course
Remission: not
reported for rapid
cyclers
Yes QUET > PLA Not reported
Bipolar disorder rapid cycling treatment review
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Vieta et al.
2007 (33)
QUET versus PLA
A priori planned
secondary analysis
for a rapid cycling
course during the
previous year in
one 8-week RCT in
acute BD-I or BD-II
depression
Rapid cyclers (n = 108):
QUET 300 mg
(n = 42)
QUET 600 mg
(n = 31)
PLA (n = 35)
Primary outcome:
change in MADRS
QUET: significantly
greater mean reductions
from baseline to week 8 in
the MADRS and second
ary efficacy measures
Clinical response rates:
QUET = 66.8%
PLA= 40%
Remission: not
reported
Yes QUET > PLA Inconclusive
effect of QUET on
treatment-
emergent
mania due
to small
number of
patients
Mood stabilizer–anticonvulsant monotherapy
Lamotrigine
Suppes et al.
2008 (23)
LTG versus LITH
Post hoc analysis
for rapid cyclers in a
16-week randomized,
open-label,
monotherapy trial in
patients with a current
depressed episode
of BD-II
Rapid cyclers within
the past 12
months (n = 68):
83% of the LTG group
69% of the LITH group
The primary outcome
variable was change
in the HDRS-17
44% completed the
study: 51% in the LTG
group and 19 (39%) in
the LITH group (p = 0.29)
For rapid cyclers: (i) both
groups showed
significant improvement
on the HDRS, with no
between-group
differences in
improvement; (ii) both
groups demonstrated
significant improvement
on the MADRS, with no
between-group
differences in
improvement; (iii) both
groups showed
significant improvement
on the YMRS, with no
significant differences
between groups; (iv) both
groups showed
significant improvement
in overall mood severity
(CGI scale), with no
between-group
differences; (v) significant
improvement on GAF
scores; (vi) there was also
a significant group-
by-visit interaction for the
GAF, with the LTG rapid
cycling group showing a
greater improvement on
the GAF; (vii) remission in
rapid cyclers: not
reported
Pharmaceutical
company
provided
medication
and reviewed
the paper
LTG = LITH Not reported
Fountoulakis et al.
120
Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Lithium
Amsterdam
et al. 2009 (17)
VENLF versus
LITH
(see above)
VENLF > LITH
Suppes et al.
2008 (23)
LTG versus LITH
(see above)
LTG = LITH
Valproate
Muzina et al.
2011 (34)
VAL versus PLA
6-week RCT in BD-I
or BD-II depression
N = 54:
BD-I (n = 20)
BD-II (n = 34)
(67% rapid cycling
during the previous
12 months)
VAL (n = 26)
PLA (n = 28)
The primary outcome
measure was mean
change from baseline
to week 6 on the
MADRS total score
(i) No separate
results for rapid
cyclers; however,
the majority
were rapid cyclers;
(ii) DIVAL treatment
produced statistically
significant improvement
in MADRS scores
compared with
placebo from week 3
onward; (iii)
no separation
between VAL and
PLA for those
with BD-II diagnoses;
(iv) remission: no
separate results
for rapid cyclers
Response rates:
VAL: 38.5%
PLA: 10.7% (3 of 28)
p = 0.017
Remission rates:
VAL: 23.1%
PLA: 10.7%
(3 of 28)
p = 0.208
Yes VAL > PLA 6 patients
on PLA and
8 on VAL
switched into
(hypo)
mania; their
rapid cycling status
was not reported
Suppes et al.
2005 (21)
OLAN versus DIVAL
(see above)
OLAN = DIVAL
Mood stabilizer–anticonvulsant combinations
Wang et al.
2010 (35)
LTG ± (LITH ± VAL) versus
PLA ± (LITH ± VAL)
Rapid cycling de
pressed patients with
a recent SUD not
meeting criteria for
MADRS, YMRS, and
GAF response after
16 weeks of open-
label treatment with
LITH + VAL were
randomized to
a 12-week,
double-blind
addition
N = 36:
LTG (n = 18)
PLA (n = 18)
Primary outcome:
change in MADRS
Eight patients per arm
completed the study
The changes in MADRS
and YMRS total scores
and rates of response
and remission did
not differ
No LTG = PLA Not reported
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Mood stabilizer–anticonvulsant ± antidepressant
Post et al. 2006 (24) BUP ± MS versus
sertraline ± MS
versus VENLF ± MS
Post hoc analysis for
rapid cycling
(prior history)
patients with BD-I
or BD-II depression
in a 10-week
randomized
trial
N = 174 (27% with a
prior history of
rapid cycling)
Primary outcomes:
AD response, AD
remission, and
AD-related switch
into mania or
hypomania
(i) Separate results
for AD response
and remission not
reported for rapid
cycling patients;
(ii) the difference
between the three
medications in
the risk for
switching was
highly significant
among rapid
cycling patients;
(iii) BUP had a
significantly
lower risk
than VENLF,
whereas there
was no significant
difference between
BUP and sertraline
or between sertraline
and VENLF;
(iv) remission: not
reported for rapid
cyclers
Pharmaceutical
companies
provided
medications
BUP > VENLF
in avoiding
switching
BUP > VENLF
in avoiding
mood
switching
Mood stabilizer–anticonvulsant ± ethyl-eicosapentanoate
Keck et al. 2006 (36) MS versus MS ± EPA
4-month, RCT,
adjunctive trial
of EPA 6 g ⁄day
in the treatment
of bipolar
depression and
rapid cycling
(within the
previous 12
months) BD
N = 59:
EPA (n = 31)
PLA (n = 28)
Efficacy
measures:
early study
discontinuation,
changes from
baseline in
depressive
symptoms (IDS
total score) and
in manic
symptoms (YMRS
total score), and
manic exacerbations
(switches)
No significant
differences were
found on any
outcome measure
between the EPA
and PLA groups
Remission: not
reported
Yes MS = MS + EPA No
significant
differences
in manic
switch rates
between
EPA and PLA
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Relapse prevention
Reviews
Tondo et al.
2003 (27)
Meta-analysis of
16 studies for
effects
of rapid cycling
status and treatment
type on clinical
outcome
(non-improvement
or recurrence per
exposure-time)
3 ⁄ 16 studies were
randomized
(i) Rapid cycling
was associated with
clinical non-improvement
with all active treatments
evaluated; (ii) rapid
cycling was associated
with higher recurrence
under all treatments
evaluated; (iii) time to
relapse: no data
The crude rate-estimate
for recurrence for rapid
cycling subjects pooled
across all study arms was
higher (by 1.85-fold) than
for non-rapid cycling
subjects (2.31 ⁄ 1.25% ⁄month)
Pooled recurrence
rates from low to
high, ranked:
LITH: 2.09% ⁄month
CBZ: 2.87% ⁄month
VAL: 3.63% ⁄month
LTG: 8.57% ⁄month
PLA: 12.5% ⁄month
No LITH = CBZ Not reported
Antipsychotic monotherapy
Aripiprazole
Muzina et al.
2008 (37)
ARI versus PLA
Post hoc analysis of
one 100-week, RCT in
rapid cycling
(previous 12 months)
patients with BD-I
(most recently
manic ⁄mixed)
Rapid cyclers
(n = 28):
ARI (n = 14)
PLA (n = 14)
Primary measure:
time to relapse
No data on number of
relapses
Time to relapse was
significantly longer with
ARI versus PLA at
week 100
Yes ARI > PLA Not reported
Olanzapine
Vieta et al.
2004 (19)
OLAN versus PLA
(see above)
(i) Non-rapid cyclers had a
better long-term outcome;
(ii) non-rapid cyclers were
more likely to experience
a symptomatic remission
in one year and were less
likely to experience a
recurrence, especially
depression; (iii) they also
were less likely to be
hospitalized and to make
a suicide attempt; (iv) no
data on time to relapse
Yes Non-rapid
cyclers > rapid
cyclers
Rapid
cyclers
were more
likely to
experience
a
depressive
switch
Bipolar disorder rapid cycling treatment review
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Quetiapine
Langosch et al. 2008 (38) QUET versus VAL
12-month, open-label,
randomized,
parallel-group
monotherapy
N = 38 remitted or
partly remitted
patients with rapid
cycling BD (not
specified whether it
referred to lifetime
or past year cycling
history):
QUET (n = 22)
VAL (n = 16)
Primary outcome:
not defined
(i) Life Chart Method
data: QUET: significantly
fewer moderate to
severe depressive days
than patients on VAL
while they did not differ
in the number of days
with manic or hypomanic
symptoms; (ii) no
significant differences in
responder rates, YMRS,
MADRS, HDRS
reductions and the
frequency of mood
swings; (iii) no results
were provided
regarding
time to relapse
Yes QUET > VAL
and QUET = VAL
No significant
differences
in the
frequency of
mood
swings
Mood stabilizer–anticonvulsant monotherapy
Carbamazepine
Denicoff et al. 1997 (25) LITH versus CBZ
versus LITH ±CBZ
Post hoc sub-analysis
in patients with a past
history of rapid cycling
of one double-blind
randomized
cross-over study
One-year treatment
with either LITH
or CBZ to one-year
cross-over to one-year
LITH + CBZ in bipolar
prophylaxis
N = 52 BD outpatients:
Rapid cyclers (n = 31)
No primary measure
defined
(i) Rapid cyclers showed
a better treatment
response to combination
than to either
monotherapy, according
to CGI ratings; (ii) a past
history of rapid cycling
predicted a CBZ non-
response; (iii) the number
of relapses and the time
to relapse for rapid
cyclers were not
reported
Yes LITH + CBZ
> LITH > CBZ
Not reported
Lamotrigine
Goldberg et al. 2008 (40) LTG versus PLA
Randomized trial in
current manic,
hypomanic, depressive, or
mixed-episode rapid
cyclers (previous year),
assessing daily and
weekly mood shifts.
Post hoc comparison in
subjects who
achieved euthymia
across weeks
Rapid cyclers (n = 177):
LTG (n = 90)
PLA (n = 87)
Primary measure:
not specified
(i) Patients taking LTG
were 1.8 times more likely
than those taking PLA to
achieve euthymia at least
once ⁄week in 6 months
as assessed by the Life
Chart Method; (ii)
subjects taking LTG had
an increase of 0.69 more
days per week euthymic
as compared with those
taking PLA; (iii) number of
relapses and time to
relapse were not reported
Yes LTG > PLA Not reported
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Calabrese et al.
2000 (39)
LTG versus PLA
6-month double-blind,
randomized,
placebo-controlled
study in rapid cycling
(previous year) BD-I
and BD-II patients.
Initially, LTG was
added to current
regimens during an
open-label treatment
and then the other
psychotropics were
tapered off
N = 177:
LTG (n = 90)
PLA (n = 87)
Primary measure: time
to additional
pharmacotherapy for
emerging symptoms
6-month stabilization rates:
LTG = 41%
PLA = 26%
(i) No difference between
treatment groups in time
to additional
pharmacotherapy for
emerging symptoms
(primary outcome
measure); (ii) time to any
premature discontinuation
was significantly longer for
LTG; (iii) more patients
without relapse in the LTG
group for BD-II but not
BD-I subtype; (iv) no data
were reported in terms of
number of relapses
Yes LTG > PLA
May be effective in
BD-II but not in
BD-I subpopulation
Not reported
Walden et al.
2000 (41)
LTG versus LITH
One-year open,
randomized trial in
manic patients with
rapid cycling (past
year) disorder
N = 14:
LTG (n = 7)
LITH (n = 7)
Primary measure:
not defined
LITH group:
3 ⁄ 7 (43%): fewer than
4 affective episodes
(depressive, manic,
hypomanic, or mixed
4 ⁄ 7: (57%) 4 or more
episodes
LTG group:
6 ⁄ 7 (86%) fewer than
4 episodes
1 ⁄ 7: (14%) more than
4 affective episodes
3 ⁄ 7 (43%): without any
further affective episodes
There was no evidence of
a preferential AD versus
antimanic efficacy; time to
relapse not reported
Not reported LTG > LITH Not reported
Lithium
Kemp et al.
2009 (42)
LITH versus LITH ± DIVAL
6-month, double-blind,
randomized parallel-
group study in rapid
cycling (past 12 months)
patients with co-occurring
substance abuse or
dependence and recently
stabilized disorder
following combination
treatment with
LITH and VAL
Rapid cyclers (n = 31):
LITH (n = 16)
LITH + DIVAL (n = 15)
Primary measure: time to
treatment for a mood
episode
Relapse rates:
LITH = 56%
LITH + DIVAL = 53%
LITH monotherapy
did not differ from
LITH + DIVAL in terms
of rates or time to relapse
No data for treatment
effects on the number
of relapses were
presented
Pharmaceutical
industry provided
study medication
LITH = LITH + DIVAL Not reported
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Table 1. (Contiuned).
Study design Efficacy
Funding from the
pharmaceutical
industry Conclusionsa
Affective
switching
rates
Calabrese et al.
2005 (43)
LITH versus DIVAL
20-month, double-
blind, randomized,
parallel-group
comparison in rapid
cycling (previous
year) patients with
recently stabilized
disorder following
combination treatment
with LITH and VAL
Rapid cyclers (n = 60):
LITH (n = 32)
DIVAL (n = 28)
Primary outcome
measure: time to
treatment for a mood
episode (relapse)
Relapse rates:
LITH = 56%
DIVAL = 50%
There were no significant
group differences in rates
or time to relapse
The comparative treatment
effects on the number of
relapses were not
presented
Industry provided
only study
medications
LITH = DIVAL Not reported
Walden et al.
2000 (41)
LTG versus LITH
(see above)
LTG > LITH
Denicoff et al.
1997 (25)
LITH versus CBZ
versus LITH ± CBZ
(see above)
LITH + CBZ > LITH > CBZ
Valproate
Calabrese et al.
2005 (43)
LITH versus DIVAL
(see above)
LITH = DIVAL
Mood stabilizer–anticonvulsant combination
Kemp et al.
2009 (42)
LITH versus LITH ± DIVAL
(see above)
LITH = LITH + DIVAL
Denicoff et al.
1997 (25)
LITH versus CBZ
versus LITH ± CBZ
(See above)
LITH + CBZ > LITH > CBZ
Antidepressant continuation ⁄discontinuation
Ghaemi et al.
2010 (26)
Planned subgroup
analyses for rapid
cyclers (during the
previous year) in a 1–
3-year open, random
assignment study in
bipolar depression.
MS were continued in
both groups
N = 35
Primary outcome: mean
change on the
depressive subscale
of the STEP-BD Clinical
Monitoring Form
Rapid cycle course
predicted 3 times more
depressive episodes with
AD continuation
Rapid cyclers had more
depressive episodes,
shorter episode latency,
and fewer weeks in
remission, independently
of treatment
No AD discontinuation >
AD continuation
Not reported
for rapid
cyclers
AD = antidepressant; AP = antipsychotic, ARI = aripiprazole; BD = bipolar disorder; BD-I = bipolar I disorder; BD-II = bipolar II dis-
order; BUP = bupropion; CBZ = carbamazepine; CGI = Clinical Global Impression; DIVAL = divalproex; EPA = ethyl-eicosapentano-
ate; GAF = Global Assessment of Functioning; HDRS = Hamilton Depression Rating Scale; IDS = Inventory for Depressive
Symptomatology; LITH = lithium; LTG = lamotrigine; MADRS = Montgomery-A˚sberg Depression Rating Scale; MDE = major depres-
sive episode; MS = mood stabilizer; OLAN = olanzapine; PANSS = Positive and Negative Syndrome Scale; PLA = placebo;
QUET = quetiapine; RCT = randomized, controlled trial; STEP-BD = Systematic Treatment Enhancement Program for Bipolar Disorder;
SUD = substance use disorder; VAL = valproate; VENLF = venlafaxine; XR = extended release; YMRS = Young Mania Rating Scale.
aThe = sign indicates equal efficacy; >indicates more effective; <indicates less effective.
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adequately powered is noted as a limitation by the
authors.
Venlafaxine. In another randomized trial of 12
weeks duration, Amsterdam et al. (17) compared
the safety and antidepressant eﬃcacy of venlafaxine
versus lithium monotherapy in patients presenting
with a major depressive episode of bipolar II
disorder. The study was not speciﬁcally powered
to detect diﬀerences in eﬃcacy or mood conversion
between groups with and without a lifetime history
of rapid cycling, and the post hoc analyses of these
groups were exploratory. The primary outcome
measure of the study was the HDRS-28 rating score
suggesting that venlafaxine was associated with a
greater reduction in HDRS-28 scores (p = 0.001)
when compared with the lithium group which was
independent of cycling status (p = 0.358). Amster-
dam et al. also reported a higher rate of responders
(p = 0.021) and remitters (p = 0.001) in the rapid
cycling group. Interestingly, venlafaxine did not
result in a higher proportion of mood conversions
when compared to lithium in either the rapid or
non-rapid cycling patients. This study received no
funding from the pharmaceutical industry.
Antipsychotic monotherapy
Aripiprazole. In a post hoc analysis of two three-
week randomized, controlled trials, Suppes et al.
(29) assessed the eﬃcacy and safety of aripiprazole in
subpopulations of patients experiencing an acute
bipolar I manic or mixed episode. The primary
eﬃcacy outcome measure for this study was mean
change from baseline to week 3 in Young Mania
Rating Scale (YMRS) total scores. Patients with a
rapid cycling course during the previous year dem-
onstrated signiﬁcantly greater improvements in
YMRS with aripiprazole than placebo (p < 0.01).
In addition, in the rapid cycling subgroup, both
responder and remitter rates were statistically sig-
niﬁcantly greater in patients receiving aripiprazole
(p = 0.0018 and p = 0.0070, respectively). This
study did not present data on mood conversion and
was funded by a pharmaceutical company.
Olanzapine. Tohen et al. (30) studied the eﬀects of
olanzapine in the treatment of acute mania in a
random-assignment, double-blind, placebo-con-
trolled parallel group study of three weeks
duration. Following a two- to four-day screening
period, qualiﬁed patients were assigned to either
olanzapine (n = 70) or placebo (n = 69).
In the secondary analysis of this data set, Sanger
et al. (31) suggested that olanzapine was eﬀective
in reducing symptoms of mania (change in YMRS
total score from baseline to endpoint which was the
primary eﬃcacy measure) and was well tolerated in
patients with bipolar I disorder with a rapid cycling
course in the preceding year. The authors did not
report whether olanzapine aﬀected conversion
rates into the opposite polarity. This analysis was
funded by the pharmaceutical industry.
Data from the Tohen et al. study (30) and a
second study that used a similar design (32) were
pooled to conduct a post hoc analysis of diﬀerences
in treatment responses in patient subgroups by
Baldessarini et al. (18). They found similar olanza-
pine superiority to placebo in responsiveness (pro-
portion of subjects attaining ‡ 50% reduction in
YMRS scores, which was the primary outcome
measure) in patients with a rapid cycling course
during the previous year, compared to non-rapid
cycling patients. In this study, which had received
funding from the pharmaceutical industry, no data
on aﬀective switch rates were shown.
Similarly, Vieta et al. (19) analyzed data pooled
from the same studies with the aim to compare
demographic, clinical, and outcome measures be-
tween bipolar disorder patients with a manic
episode that had either a rapid or a non-rapid
cycling course during the previous year. This
analysis also included an open-label treatment
study with olanzapine which followed patients for
up to a year after completion of the ﬁrst trial (30).
The resulting total number of patients was 254; 90
of whom were rapid cyclers (44 had received
olanzapine and 46 had received placebo). Vieta
et al. (19) found that improvement of mania was
similar in rapid cyclers and non-rapid cyclers, but
rapid cyclers showed an earlier response. Rapid
cyclers were more likely to convert into depression
compared with non-rapid cyclers. This study had
received sponsorship, in part, from the pharma-
ceutical industry.
In another post hoc analysis of the two above-
mentioned randomized, controlled trials examining
olanzapine, Shi et al. (20) investigated the eﬀects of
olanzapine on the cognitive factor of the Positive
and Negative Syndrome Scale (PANSS) which was
the primary outcome of the relevant study and
presented results for patients with a rapid cycling
status. They reported that olanzapine-treated
patients showed modest but signiﬁcant improve-
ment in PANSS-Cognitive score regardless of rapid
cycling course. However, it should be noted here
that the authors did not clarify whether rapid
cycling course involved the previous year or
patients lifetime history. This study also received
funding from the pharmaceutical industry.
Suppes et al. (21) conducted a post hoc analysis
of one 47-week, randomized, double-blind study
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that compared olanzapine (5–20 mg ⁄day) to dival-
proex sodium (500–2500 mg ⁄day) in 251 patients
suﬀering from a bipolar manic or mixed episode.
The objective of this study was to examine whether
rapid cycling during the previous year aﬀects
treatment response. The change in YMRS was
used as the primary outcome measure. Of the 251
randomized patients, 144 were classiﬁed as rapid
cyclers (76 had received olanzapine and 68 had
received divalproex). This post hoc analysis
showed that rapid cycling patients did less well
during the extended observation period than non-
rapid cycling patients, regardless of treatment. Of
note, rapid cycling patients receiving divalproex
appeared to be at some advantage over non-rapid
cycling patients receiving divalproex in terms of
manic symptom improvement. However, contin-
ued improvement was not observed beyond the
ﬁrst few weeks, though initial eﬀects were sus-
tained. Another signiﬁcant ﬁnding was that among
rapid cycling patients, olanzapine and divalproex
appeared equal in terms of YMRS changes from
baseline to endpoint, while among non-rapid
cycling patients, olanzapine appeared superior.
No signiﬁcant diﬀerence between rapid and non-
rapid cyclers was revealed in Clinical Global
Impression (CGI) Mania or Bipolar Severity
(CGI-BP), or HDRS. Rapid cyclers were shown
to respond diﬀerently from non-rapid cyclers over
time, independent of treatment. They also demon-
strated a non-signiﬁcant trend to experience
depression more often than non-rapid cyclers,
independent of treatment. This study received
pharmaceutical company funding.
In summary, the secondary analyses of the
pivotal olanzapine trials showed that olanzapine
is equally eﬀective in reducing manic symptoms in
rapid and non-rapid cyclers. There is evidence that
its antimanic eﬀect appears earlier in rapid cyclers
who are also more likely to experience a switch into
depression. Olanzapine is similar to divalproex
against manic symptoms and could have a positive
eﬀect on cognitive symptoms in this bipolar
disorder subpopulation.
Quetiapine. Vieta et al. (33) conducted an a priori
sub-analysis of data from adult patients with a
diagnosis of bipolar depression and a rapid cycling
disease course during the previous year. The
subjects were recruited from a multicenter trial
that examined the eﬃcacy of quetiapine. Patients
were randomized to eight weeks of treatment with
either quetiapine at 600 mg ⁄day (n = 31), quetia-
pine at 300 mg ⁄day (n = 42), or placebo (n =
35). The primary eﬃcacy variable was change from
baseline to week 8 in Montgomery–A˚sberg Depres-
sion Rating Scale (MADRS) total score. The
analysis suggested that quetiapine monotherapy
(600 or 300 mg ⁄day) was clinically more eﬀective
than placebo in terms of both MADRS reductions
(p < 0.001) and changes in other secondary mea-
sures (CGI, HDRS, Hamilton Rating Scale for
Anxiety, Pittsburgh Sleep Quality Index, and
Quality of Life Enjoyment and Satisfaction Ques-
tionnaire scales) and was also well tolerated in the
short-term treatment of depressive episodes in
patients with bipolar I or II disorder who had a
rapid cycling disease course. The administration of
quetiapine was associated with a very low propen-
sity to cause treatment-emergent mania. Two
patients in the 600-mg group, two in the 300-mg
group, and one patient receiving placebo switched
into mania. This ﬁnding suggests that quetiapine
probably does not increase the risk of a manic
switch, although a larger sample is needed to draw
safer conclusions. This study was funded by the
pharmaceutical industry.
Similarly, in a more recent study on patients
with bipolar depression that was also sponsored by
the pharmaceutical industry, Suppes et al. (22)
reported that quetiapine monotherapy (300 mg)
was found to be more eﬀective than placebo. A
post hoc analysis for patients with and without a
rapid cycling disease course during the previous
year revealed that quetiapine was associated with
signiﬁcantly greater reductions than placebo in the
MADRS total score change from baseline to week
8. This was the primary eﬃcacy measure. Although
quetiapine was not associated with treatment-
emergent hypomania or mania for the whole
sample, its speciﬁc eﬀect on switch rates in patients
with a rapid cycling course was not reported.
Mood stabilizer–anticonvulsant monotherapy
Lamotrigine. Suppes et al. (23) presented results
involving rapid cycling patients in a study com-
paring open-label lamotrigine and lithium mono-
therapy in bipolar II disorder depression. Patients
were titrated to 200 mg ⁄day of lamotrigine over
eight weeks or at least 900 mg ⁄day of lithium over
two weeks (serum level 0.6–1.2 mEq ⁄L), and were
seen biweekly for 16 weeks. The evaluable number
of patients for eﬃcacy analyses was 90; 41 for the
lamotrigine group and 49 for the lithium group. Of
the 90 patients evaluated, 72% (n = 71) showed
rapid cycling within the previous 12 months;
79.6% in the lamotrigine group, and 66.7% in
the lithium group. A total of 40 patients (44%)
completed the study: 21 (51%) in the lamotrigine
group and 19 (39%) in the lithium group
(p = 0.29). The primary outcome variable was
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change in the HRDS-17. Both groups showed
signiﬁcant improvement from baseline to endpoint
on the HDRS-17 (p < 0.0001), with no between-
group diﬀerences (p = 0.95). No diﬀerences in
response were noted between rapid cyclers and
non-rapid cyclers. For the subset of patients with a
history of rapid cycling, both groups showed
signiﬁcant improvement on the HDRS-17
(p < 0.001) at week 16, with no between-group
diﬀerences in improvement (p = 0.39). Similarly,
in rapid cycling patients both groups demonstrated
signiﬁcant improvement on the MADRS
(p < 0.001) at week 16, with no between-group
diﬀerences in improvement (p = 0.96). Patients
with a history of rapid cycling experienced signif-
icant improvement on the YMRS (p < 0.001),
with no signiﬁcant diﬀerences between groups
(p = 0.74). Patients with a history of rapid cycling
also showed signiﬁcant improvement in overall
mood severity (CGI scale) (p < 0.001), with no
between-group diﬀerences (p = 0.43). Patients
experiencing rapid cycling showed signiﬁcant
improvement on Global Assessment of Function-
ing (GAF) scores (p < 0.001). There was also a
signiﬁcant group-by-visit interaction for the GAF
(p = 0.019), with the lamotrigine rapid cycling
group showing a greater improvement on the
GAF. The speciﬁc treatment impact on the prob-
ability of hypomanic switch in rapid cycling
patients was not reported, although both lithium
and lamotrigine were associated with a limited
switch rate in the whole sample. No patient in the
lamotrigine group and only one patient in the
lithium group met mood switch criteria. Although
the manufacturer of lamotrigine did not provide
funding for the study, it provided medication and
had the opportunity to review this paper and to
give editorial feedback (23).
Lithium. Two studies (17, 23) investigated the acute
eﬃcacy of lithium monotherapy against bipolar II
major depressive episodes in rapid cycling patients
and have been discussed above.
Valproate. Further to the study of Suppes et al. (21)
(see above), which compared valproate with ola-
nzapine, Muzina et al. (34) conducted an explor-
atory investigation of the acute eﬃcacy of
extended-release divalproex sodium compared with
placebo in patients with bipolar I or II depression
that had never been treated with a mood stabilizer.
Fifty-four patients with bipolar I (n = 20) or
bipolar II (n = 34) disorder were randomly
assigned to six-week divalproex or placebo mono-
therapy, while 67% met DSM-IV criteria for rapid
cycling. Although the authors did not report
separate results for patients with a rapid cycling
course, this study was selected for our review due
to the fact that the majority of patients were rapid
cyclers. The primary outcome measure of the study
was mean change from baseline to week 6 on the
MADRS total score. Secondary outcomes included
rates of response and remission, changes in the
CGI-BP scores and changes in anxiety symptoms
as measured by the Hamilton Anxiety Rating
Scale. Divalproex treatment was associated with
signiﬁcant improvement in MADRS scores com-
pared with placebo from week 3 onward, which
included patients with bipolar I disorder, albeit not
bipolar II disorder. Similarly, a signiﬁcantly higher
percentage of patients in the divalproex group met
response criteria compared with the placebo group
(38.5% versus 10.7%, p = 0.017). However, the
two groups did not diﬀer in the proportion of
patients achieving remission. Six patients receiving
placebo and eight receiving divalproex met criteria
for treatment-emergent hypomania ⁄mania; how-
ever, the authors did not report whether they were
rapid cyclers or not. The study was funded by the
pharmaceutical industry.
Mood stabilizer–anticonvulsant combinations
Lamotrigine addition to lithium and valproate. The
acute eﬃcacy of mood stabilizer–anticonvulsant
combinations was examined in a recent study by
Wang et al. (35) which reported the results of a
trial comparing a 12-week adjunctive treatment
with lamotrigine to ongoing treatment with lithium
plus valproate in depressed patients with rapid
cycling bipolar disorder comorbid with a substance
use disorder. The patients recruited had failed to
meet the criteria for a bimodal response following
a 16-week open-label treatment with lithium plus
divalproex, and were thereafter randomized to
receive adjunctive lamotrigine or placebo. These
criteria comprised a MADRS score lower than 19,
a YMRS score < 12, and a GAF score > 51 for
four weeks. Of the 98 patients enrolled into the
study, 36 were randomized to receive either lamo-
trigine (n = 18) or placebo (n = 18). No signiﬁ-
cant diﬀerences were found in terms of the
MADRS or YMRS change from baseline to
endpoint or rates of response and remission
between lamotrigine- and placebo-treated patients.
The eﬀects of treatment on aﬀective mood switch
were not reported. The study did not receive
funding from any pharmaceutical company.
Mood stabilizer–anticonvulsant plus antidepressant
Bupropion or sertraline or venlafaxine addition to
mood stabilizers. Post et al. (24) examined the
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relative risks of switching into hypomania or
mania associated with second-generation antide-
pressant drugs in bipolar depression. More specif-
ically, they investigated the acute eﬀects of
bupropion, sertraline, and venlafaxine as adjuncts
to mood stabilizers in a 10-week randomized trial
and presented results on patients with a prior
positive history for rapid cycling. Antidepressant
response, antidepressant remission, and antide-
pressant-related switch into mania or hypomania
were the primary outcomes of this study. However,
the separate results for rapid cycling patients were
reported only for switch rates. A strong interaction
between the rapid cycling status of patients and the
relative risk of switching was revealed for the three
medication groups. The diﬀerence between the
three medications was highly signiﬁcant among
rapid cycling patients [log rank v2 = 9.66, degrees
of freedom (df) = 2, p < 0.01]. The pattern of this
diﬀerence for the rapid cycling group was that
bupropion had a signiﬁcantly lower risk for
switching than venlafaxine (log rank v2 = 9.07,
df = 1, p < 0.01), whereas there was no signiﬁ-
cant diﬀerence between bupropion and sertraline
(log rank v2 = 1.9, df = 1, p < 0.17) or between
sertraline and venlafaxine (log rank v2 = 2.1,
df = 1, p < 0.15). Three pharmaceutical compa-
nies that manufacture bupropion, sertraline, and
venlafaxine provided the medications and pla-
cebo, but were not involved in the funding of the
study.
Mood stabilizer–anticonvulsant plus ethyl-eicosa-
pentanoate (EPA)
In a four-month, randomized, placebo-controlled
trial, Keck et al. (36) examined the eﬀects of
6 g ⁄day EPA augmentation of treatment with
mood stabilizers in patients with bipolar depres-
sion with a rapid cycling course within the
previous 12 months and reported negative results.
In this study, 31 rapid cycling patients receiving
EPA and 28 subjects receiving placebo did not
show any diﬀerence in any of the outcome
measures [early study discontinuation, changes
from baseline in depressive symptoms measured
by the Inventory for Depressive Symptomatology
total score, manic symptoms assessed by YMRS
total score, and manic exacerbations (switches)]
thus lending no support to the antidepressant
eﬃcacy of omega-3 fatty acid addition for
patients with rapid cycling bipolar disorder. The
study was partly sponsored by the pharmaceu-
tical company that also provided the study
medication.
Relapse prevention in rapid cycling bipolar disorder
Antipsychotic monotherapy
Aripiprazole. The eﬀects of aripiprazole in rapid
cycling (course within the previous year) bipolar
disorder patients who had experienced a recent
manic or mixed episode were investigated by
Muzina et al. (37) in a post hoc analysis of a 100-
week, randomized, controlled trial. This analysis
suggested that aripiprazole maintained eﬃcacy and
was generally well tolerated in the long-term
treatment of rapid cycling bipolar disorder. Time
to relapse was signiﬁcantly longer with aripiprazole
versus placebo at week 100, but it should be
mentioned that the study had a small sample size of
only 28 patients. The authors did not report
whether there was a diﬀerence between aripipraz-
ole and placebo in the number of relapses or mood
switches. This study was supported by the phar-
maceutical industry.
Olanzapine. In a study comparing olanzapine with
placebo among patients who continued open-label
olanzapine therapy for one year after three weeks
of double-blind therapy for acute mania, Vieta
et al. (19) reported that rapid cyclers were less
likely to experience a symptomatic remission
within one year (p = 0.014) and were more likely
to experience a recurrence, especially into a
depressive phase during the one-year period.
Patients were also more likely to be hospitalized
and to make a suicide attempt. Interestingly, the
mean number of new episodes in rapid cyclers
during the open-label olanzapine treatment was
1.44, suggesting that they no longer met the
criteria for the diagnosis of rapid cycling. This
study was partly supported by the pharmaceutical
industry.
Quetiapine. The long-term eﬃcacy and safety of
quetiapine were compared with those of sodium
valproate in an open-label, randomized, parallel-
group monotherapy pilot study by Langosch et al.
(38). The study included 38 remitted or partly
remitted patients diagnosed with bipolar disorder
with a rapid cycling course. However, the study
did not mention whether this course referred to
the past 12 months or to a lifetime history.
Twenty-two patients were treated with quetiapine
and 16 were treated with valproate for 12 months,
with 41% of the quetiapine patients and 50% of
the valproate patients completing the trial. Life
Chart Method data showed that patients being
treated with quetiapine had signiﬁcantly fewer
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moderate-to-severe depressive days than patients
receiving valproate [mean ± standard deviation
(SD) = 11.7 ± 16.9 days versus 27.7 ± 24.9
days; p = 0.04], while they did not diﬀer in the
number of days with manic or hypomanic symp-
toms or the frequency of mood swings. No
diﬀerences were found in responder rates or
HDRS, MADRS, or YMRS reductions between
the two groups.
Mood stabilizer–anticonvulsant monotherapy
Carbamazepine. In a prospective study of 52
outpatients with bipolar disorder, Denicoﬀ et al.
(25) evaluated the prophylactic eﬃcacies of lith-
ium, carbamazepine, and a combination of both
drugs. The patients were randomly assigned in the
double-blind study to either lithium or carbamaz-
epine for the ﬁrst year. In the second year, there
was a cross-over to the opposite drug, and then all
patients received the combination of lithium and
carbamazepine during the third year. More than
half of these patients had a past history of rapid
cycling which was associated with a better response
as assessed by CGI ratings on the combination
therapy than on either monotherapy (56.3% for
the combination, versus 28% for lithium and 19%
for carbamazepine; p < 0.05). Notably, four out
of nine rapid cycling patients who responded to the
combination did not respond to either monother-
apy. A past history of rapid cycling also predicted
carbamazepine non-response. In general, patients
experienced a signiﬁcantly lower number of epi-
sodes on the combination compared with lithium
therapy, and the mean number of days to the ﬁrst
manic episode was signiﬁcantly higher during the
combination phase. However, the speciﬁc eﬀects of
treatments on the time to relapse, on the number of
relapses, and on mood switch were not reported for
rapid cyclers. The authors received support for the
study from the pharmaceutical industry.
Lamotrigine. Calabrese et al. (39) reported on the
eﬀects of lamotrigine monotherapy in bipolar
maintenance in a sample of 182 bipolar disorder
patients with a rapid cycling course within the
previous year. The sample was derived from 324
patients with rapid cycling bipolar disorder who
initially received an open-label lamotrigine addi-
tion to their current psychotropic regimens of four
to eight weeks duration. Thereafter, stabilized
patients were tapered oﬀ other psychotropic agents
and were randomly assigned to lamotrigine or
placebo monotherapy for six months. The primary
outcome measure of this industry-sponsored study
was the time to additional pharmacotherapy for
emerging symptoms and did not diﬀer between the
lamotrigine and placebo groups. Analyses that
favored lamotrigine in secondary measures were
the time to premature discontinuation for any
reason and the percentage of patients who re-
mained stable without relapse for six months of
monotherapy. No data were presented for the
eﬀects of lamotrigine and placebo on the number
of relapses or the prevention of aﬀective mood
switch. This trial also suggested that lamotrigine
monotherapy may be eﬀective in bipolar II
disorder patients, but not in bipolar I disorder
patients.
Goldberg et al. (40) conducted a secondary
analysis of data obtained during the course of the
Calabrese et al. study (39) using the prospective
Life Chart Method which assesses daily and weekly
mood changes and found that, after adjusting for
potential confounding factors, subjects taking
lamotrigine were 1.8 times more likely to achieve
euthymia than those taking placebo at least once
per week over six months [95% conﬁdence interval
(CI): 1.03–3.13]. Subjects taking lamotrigine had
an increase of 0.69 more days ⁄week euthymic as
compared with those taking placebo (p = 0.014).
In addition to its positive ﬁndings with regard to
lamotrigine eﬃcacy, this study also supports the
use of the prospective life chart as an informative
measure for capturing ﬁne-grained longitudinal
variations in mood. The study provided no data on
the number of relapses or time to relapse, and also
received funding from the pharmaceutical industry.
In a preliminary study to explore the potential
eﬃcacy of lamotrigine in the treatment of patients
with rapid cycling bipolar disorder (four or more
mood episodes during the previous year), Walden
et al. (41) assigned 14 patients with rapid cycling
bipolar disorder to an open, randomized one-year
treatment with either lithium or lamotrigine as a
mood stabilizer. Out of the seven patients who
received lithium, three (43%) had fewer than four
episodes, and four (57%) had four or more
episodes. In the lamotrigine group, six out of seven
patients (86%) had fewer than four episodes, and
one out of seven (14%) had more than four
aﬀective episodes (depressive, manic, hypomanic,
or mixed). In fact, three out of seven (43%) of the
patients who were on lamotrigine therapy were
without any further aﬀective episodes. No data
concerning the eﬀects of lithium or lamotrigine on
time to relapse or on the probability of a mood
switch were reported. The study produced no
evidence of a preferential antidepressant versus
antimanic eﬃcacy, but the authors admitted that
their sample size was too small to examine this
issue. Although the study suggests that lamotrigine
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is eﬀective, it also suggests that lithium is associ-
ated with a suboptimal response in rapid cycling
bipolar disorder. The authors did not report
whether they had received any funding from the
pharmaceutical industry.
Lithium. Further to the Walden et al. study (41),
which compared lithium with lamotrigine, and that
of Denicoﬀ et al. (25), which compared lithium
with valproate, a recent six-month, double-blind,
parallel-group study by Kemp et al. (42) compared
the prophylactic eﬀects of lithium monotherapy
with those of the combination of lithium plus
divalproex in 31 patients suﬀering from rapid
cycling bipolar disorder and co-occurring sub-
stance abuse or dependence. The study was a
continuation of an open-label acute stabilization
phase of 149 patients who initially received the
combination of lithium with divalproex but were
then randomly assigned either to remain on com-
bination treatment or to discontinue divalproex
and receive lithium monotherapy. Lithium mono-
therapy did not diﬀer from the combination of
lithium plus divalproex in preventing relapse of
mood episodes. The rates of relapse into a mood
episode were 56% for lithium versus 53% for the
combination, with a median time to recurrence of
15.9 weeks versus 17.8 weeks, respectively. How-
ever, it should be noted that the majority of
patients (79%) discontinued the preceding open-
label phase, thus limiting the number of patients
who participated in the following double-blind
study. The authors did not provide comparative
data on the number of relapses in the two groups,
nor on the eﬀects of treatments on mood switch.
The study did not receive funding from the
pharmaceutical industry, which only provided
study medications.
In another double-blind, parallel-group trial,
Calabrese et al. (43) reported on 60 recently hyp-
omanic ⁄manic patients with recently stabilized
rapid cycling bipolar disorder who had experienced
a persistent response for at least six months to
combined treatment with lithium and divalproex.
Patients were randomly assigned to either lithium
or divalproex monotherapy for 20 months using a
balanced design after stratiﬁcation for illness type
(bipolar I disorder versus bipolar II disorder). The
results indicated that divalproex was not more
eﬀective than lithium in the long-term management
of rapid cycling bipolar disorder since no signiﬁ-
cant diﬀerences were found in rates of, or time to
relapse to, any mood episode between the two
treatment groups. The relapse rates into any mood
episode for those assigned to lithium versus
divalproex were 56% and 50%, respectively.
However, the relatively small sample size and the
eﬀects of lithium discontinuation limit the gener-
alizability of these ﬁndings. The authors did not
present the comparative eﬀects of lithium on the
number of relapses or on mood switch and
acknowledge that the pharmaceutical industry
provided study medications but not funding.
Valproate. The study by Calabrese et al. (43)
assessed the eﬀects of valproate in comparison
with lithium monotherapy in the prevention of
relapse in rapid cycling bipolar disorder and has
been reviewed above.
Mood stabilizer–anticonvulsant combination
The results of two studies by Denicoﬀ et al. (25)
and Kemp et al. (42) that reported the eﬃcacy and
safety of mood stabilizer combination in the
prevention of relapse in rapid cycling bipolar
disorder have been discussed above. They included
the combinations of lithium ⁄ carbamazepine (25)
and lithium ⁄valproate (42) and produced contra-
dictory results. Whereas the lithium–valproate
combination was not found to be superior to
lithium monotherapy in preventing mood episodes
in rapid cyclers, the history of rapid cycling was
associated with a better response in the lithium–
carbamazepine combination group than on either
monotherapy.
Antidepressant continuation versus discontinua-
tion
Ghaemi et al. (26) recently reported the eﬀects of
antidepressant discontinuation after acute recovery
of bipolar depression in 70 patients with bipolar
depression from the Systematic Treatment
Enhancement Program for Bipolar Disorder
(STEP-BD) study. They found that a rapid cycling
course predicted three times more depressive epi-
sodes with antidepressant continuation. Rapid
cycling was an independent predictor for shorter
episode latency, increased number of depressive
episodes, and fewer weeks in remission. However,
the authors noted that these results need replica-
tion in a larger study of a rapid cycling population,
since the number of patients with a rapid cycling
course in their study was small (n = 17). This
study did not receive any funding from the
pharmaceutical industry.
Meta-analysis
Tondo et al. (27) conducted a review and meta-
analysis of 16 studies examining the long-term
treatment of rapid cycling, which included three
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randomized trials and 13 non-random, open-label
or naturalistic studies. They estimated that the
prevalence of rapid cycling was 15.4%. The
authors also conﬁrmed that rates of recurrence
were higher in rapid cyclers versus non-rapid
cyclers, a ﬁnding indicating that rapid cycling
bipolar disorder is a treatment-resistant condition.
The crude rate estimate for recurrence for rapid
cycling subjects pooled across all study arms was
higher (by 1.85-fold) than for non-rapid cycling
subjects (2.31 versus 1.25% ⁄month). Pooled
recurrence rates, from low to high, ranked as
follows: lithium (2.09% ⁄month), carbamazepine
(2.87% ⁄month), valproate (3.63% ⁄month), lamo-
trigine (8.57% ⁄month), and placebo (12.5% ⁄
month). The authors also report that no clear
advantage was found for any treatment and,
contrary to previous beliefs, anticonvulsants
demonstrated no superiority over lithium. How-
ever, the studies reviewed did not permit a direct
comparison of the treatment eﬀects of diﬀerent
agents. Only lithium and carbamazepine could be
directly compared meta-analytically in rapid
cycling patients and this comparison revealed no
diﬀerence in eﬃcacy. This meta-analysis, which
was not sponsored by the pharmaceutical industry,
did not report mood-switching rates following
treatments or the possible role of industry in the
results. It also did not provide data on the time to
relapse for the diﬀerent treatments.
In terms of adverse events, the known adverse-
eﬀect proﬁle of each agent was conﬁrmed by most
studies. Interestingly, one study found that rapid
cyclers report severe adverse eﬀects more
frequently compared to non-rapid cyclers (19).
Discussion
This is the ﬁrst paper to review the randomized
trial clinical data on the eﬃcacy of various treat-
ments in patients with rapid cycling bipolar disor-
der. Most studies included in this paper examined
the eﬃcacy and adverse eﬀects of various pharma-
cological treatments for patients with rapid cycling
bipolar disorder. Our report also analyzed studies
comparing treatment eﬀects on rapid versus non-
rapid cyclers, providing useful information on the
comparative treatment responsiveness of these
bipolar subpopulations. Previous reviews and
meta-analyses that have examined the treatment
responses of patients with rapid cycling have
included mostly naturalistic studies (3, 27).
Although the naturalistic design could provide
important clinical information, especially when
adequately randomized, controlled, and prospec-
tive trials are not available, it cannot control for
numerous treatment factors, such as severity of
illness, psychotropic dose, total time of drug
exposure, types of medications used, or the pres-
ence of concomitant medications. Thus, it cannot
establish causality in treatment response or eﬀec-
tively compare existing treatments, a limitation
that can only be avoided by randomized studies.
Despite having a randomized design, the studies
that we examined for the purposes of the present
review were not devoid of other limitations. The
majority: (i) had a small sample size, (ii) presented
post hoc analyses of data in rapid cyclers, (iii)
lacked a placebo-control group, and (iv) had a
short duration of follow-up periods. Notwith-
standing these limitations, the main ﬁndings of
the present review are: (i) rapid cycling patients do
worse in follow-up than patients without rapid
cycling; (ii) the acute responsiveness to treatment
of rapid cycling patients in comparison with non-
rapid cycling patients indeed remains inconclusive;
(iii) lithium and anticonvulsants have comparable,
albeit relatively low, eﬃcacies in rapid cyclers; (iv)
the data on the usefulness of the combination of
anticonvulsants compared with anticonvulsant
monotherapy in rapid cyclers are contradictory;
(v) the atypical antipsychotics aripiprazole, ola-
nzapine, and quetiapine are eﬀective in acute
bipolar episodes of rapid cyclers; (vi) olanzapine
is equally eﬀective to anticonvulsants during acute
treatment; (vii) aripiprazole, olanzapine, and que-
tiapine appear promising for the maintenance of
response in rapid cyclers; and (viii) there is an
association between antidepressant use and the
presence of rapid cycling, although the existence of
a causal relationship cannot yet be established.
The few existing studies support the hypothesis
that rapid cycling patients show a less favorable
long-term outcome than non-rapid cycling patients
and that initial responses do not predict long-term
eﬃcacy (19, 27). These ﬁndings have important
therapeutic implications and, certainly, need repli-
cation in studies with adequate duration. Another
important issue that also needs to be further
investigated is whether rapid cycling is a charac-
teristic that persists in time. During one random-
ized trial that explored this issue, Vieta et al. (19)
found that the rapid cycling patients who received
an open-label olanzapine treatment for one year
experienced a mean number of fewer than four
episodes. This is in agreement with the previous
studies that suggested that rapid cycling status is
not necessarily a sustained characteristic in all
cases of rapid cycling bipolar disorder (6, 7, 44).
There are no clear data concerning the diﬀeren-
tial impact of treatment against acute states, of
either mania or depression, in rapid cyclers versus
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non-rapid cyclers. Although earlier reports sug-
gested that rapid cycling is associated with inade-
quate treatment response (2, 8), two recent
randomized studies showed similar treatment
eﬀects in both bipolar subgroups (19, 22). Inter-
estingly, in one of the two, the improvement in
manic symptoms was found to occur earlier in
rapid cycling patients (19).
Recent data cast doubt on the initial opinion
that rapid cyclers are refractory to lithium treat-
ment and should be treated with other mood
stabilizers (2, 10). This earlier view was mainly
supported by comparing studies using lithium
alone against studies using anticonvulsants alone
without a direct comparison of the two treatments
following a proper randomization. In the few
randomized studies that have directly compared
the eﬀects of lithium with those of anticonvulsants,
the two treatments appeared to be equivalent in
eﬃcacy in rapid cycling patients. Indeed, lithium
prophylaxis was shown to be at least as eﬀective as
divalproex in rapid cycling bipolar disorder (43)
and showed a comparable eﬃcacy with carbamaz-
epine (25). However, it should be noted here that in
both studies monotherapy with either lithium or
one of the other two mood stabilizers demon-
strated a relatively low eﬃcacy.
The study by Denicoﬀ et al. (25) also examined
another important issue: the comparative eﬃcacy
of lithium and carbamazepine combination versus
monotherapy for treating rapid cycling bipolar
disorder. It suggested that rapid cyclers show a
better response to combination treatment than
monotherapy. On the contrary, the prophylactic
eﬀect of lithium monotherapy was not found to
diﬀer from that of the combination of lithium plus
valproate according to a more recent study (42),
thus leaving the question of whether anticonvul-
sant co-treatment is better than monotherapy still
unanswered. To the best of our knowledge, no
randomized studies have examined the therapeutic
value of combination treatments of mood stabiliz-
ers with atypical antipsychotics in rapid cycling
patients.
Interest has been growing in the therapeutic
potential of atypical antipsychotics in bipolar
disorder (45, 46). Olanzapine is eﬀective when used
alone in the acute management of manic or mixed
patients with a rapid cycling course (19, 31).
Similarly, there have been positive results for
aripiprazole (29) and quetiapine (22, 33) in bipolar
mania and depression, respectively. The latter
ﬁnding is particularly important, since patients
with rapid cycling bipolar disorder present more
often in the depressed phase of their disease (5, 26,
47). Recent studies also suggest that the acute
treatment eﬀects of mood stabilizers appear to be
equal to those of olanzapine in rapid cyclers
presenting with manic or mixed states (21). How-
ever, more studies are needed using other atypical
antipsychotics and mood stabilizers in order to
draw a safe conclusion on the relative eﬃcacy of
these agents in rapid cycling bipolar disorder.
The eﬃcacy of aripiprazole (37), olanzapine (19),
and quetiapine (38) monotherapy extends beyond
the acute treatment to bipolar maintenance in
rapid cycling bipolar disorder. An interesting
ﬁnding that needs further exploration was that
quetiapine seems more eﬀective for the prophylaxis
of exacerbations of depressive than manic symp-
toms. The role of typical or other atypical anti-
psychotics as well as their comparative eﬃcacies in
acute and prophylactic treatment of rapid cycling
bipolar disorder remain to be investigated in future
studies.
The most important issue in the management of
rapid cycling bipolar disorder is probably not the
acute eﬃcacy of existing medications but their
potential for relapse prevention. Indeed, the
original paper by Dunner and Fieve (2) studied
prophylactic treatment rather than acute respon-
siveness of rapid cyclers. The reason that the
present review has mainly covered data concerning
the acute treatment of rapid cycling bipolar disor-
der is that studies examining long-term stabiliza-
tion of rapid cycling bipolar disorder patients are
even fewer and therefore most needed.
A central question in the long-term treatment of
bipolar disorder, and more speciﬁcally rapid
cycling, is whether antidepressants are of beneﬁt
or if they destabilize the course of illness (10, 11).
Previous observational studies have yielded incon-
sistent ﬁndings concerning antidepressant eﬀects in
rapid cycling patients (6, 48–51). Although the
existing randomized studies have not systemati-
cally investigated this issue, they suggest that
antidepressants might relate to rapid cycling (11,
26). The etiological nature of this relationship
remains to be further delineated.
The above studies have additionally examined
the side eﬀects that emerged during treatment of
rapid cycling bipolar disorder and, as expected, the
known proﬁles of the agents used were conﬁrmed.
However, one study that examined the eﬃcacy of
olanzapine also found that rapid cyclers report
severe adverse eﬀects more frequently compared to
non-rapid cyclers (19). This ﬁnding deserves fur-
ther investigation since it has important clinical
implications.
A philosophical issue is raised after reviewing the
literature on the treatment of rapid cycling bipolar
disorder. Undoubtedly, there is an utmost clinical
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need to deﬁne the most eﬀective treatments for this
bipolar subtype. However, there are only seven
randomized controlled clinical trials that have been
designed to address it directly (28, 35, 36, 39, 40,
42, 43), two of which recruited rapid cycling
patients with a substance abuse disorder, therefore
limiting the generalizability of their ﬁndings (35,
42). Most existing data are derived from secondary
analyses carried out mostly on results from indus-
try-organized trials and open-label or naturalistic
studies. Secondary analyses are usually not ade-
quately powered to detect diﬀerences between
subgroups. In these analyses, although a positive
ﬁnding with regard to the treatment eﬃcacy of any
agent in rapid cycling subpopulations has clinical
value, a negative one cannot rule out the possibility
of a beneﬁcial treatment eﬀect. On the other hand,
the presence of publication bias needs also to be
taken into account. It is well known that secondary
analyses of clinical trials are highly subject to
publication bias, because generally only positive
ﬁndings are published. Accordingly, should one
attempt to extract some recommendations from
this insuﬃcient material, even if these recommen-
dations will be questionable? We have positively
answered this question, reviewed the existing data,
and suggested some preliminary recommendations.
However, we fully acknowledge that these recom-
mendations unavoidably carry the risk of being
rejected by future trials, free from methodological
limitations. The pharmaceutical industry remains a
major source of bias through selective reporting
and publishing, which could inﬂuence the reliabil-
ity of treatment guidelines and could also aﬀect our
recommendations (52). In order to facilitate the
interpretation of our ﬁndings, the role of the
pharmaceutical industry in the funding of each
study is shown in Table 1.
In conclusion, the present review suggests that
the current data on the treatment of rapid cycling
bipolar disorder patients need to be enriched by
more rigorously designed studies. The delineation
of the beneﬁts and risks of the existing medications
and their combinations in diﬀerent phases of rapid
cycling bipolar disorder and, in particular, main-
tenance treatment through randomized controlled
trials recruiting adequately powered samples of this
speciﬁc patient population should be a research
priority. Only when such research has been carried
out may recommendations concerning treatment of
rapid cycling bipolar disorder be safely given.
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